See more : Mercury Biopharmaceutical Corporation (6932.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of IMARA Inc. (IMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IMARA Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Maoye International Holdings Limited (0848.HK) Income Statement Analysis – Financial Results
- Monmouth Real Estate Investment Corporation (MNR-PC) Income Statement Analysis – Financial Results
- Jyske Invest Obligationer og Aktier KL (JYIOBAKKL.CO) Income Statement Analysis – Financial Results
- Nagase Brothers Inc. (9733.T) Income Statement Analysis – Financial Results
- Howden Joinery Group Plc (HWDN.L) Income Statement Analysis – Financial Results
IMARA Inc. (IMRA)
About IMARA Inc.
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.94M | 38.44M | 32.15M | 19.01M | 8.24M |
| General & Administrative | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Other Expenses | -97.00K | -175.00K | -145.00K | 75.00K | 0.00 |
| Operating Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Cost & Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Interest Income | 943.00K | 233.00K | 483.00K | 578.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -69.39M | 99.00K | 97.00K | 33.00K | -660.00K |
| EBITDA | -68.66M | -51.34M | -41.60M | -24.08M | -11.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 730.00K | -51.44M | -41.70M | -24.12M | -10.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 846.00K | 58.00K | 338.00K | 653.00K | -660.00K |
| Income Before Tax | 1.58M | -51.38M | -41.36M | -23.46M | -11.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 88.00K | -233.00K | -483.00K | -578.00K | 0.00 |
| Net Income | 1.58M | -51.15M | -40.88M | -22.89M | -11.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| EPS Diluted | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| Weighted Avg Shares Out | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
| Weighted Avg Shares Out (Dil) | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
Imara Inc (NASDAQ: IMRA) has announced a change to the primary endpoint for the Ardent Phase 2 trial of tovinontrine (IMR-687) in sickle cell disease. Imara is a biopharmaceutical company focused on therapeutics for rare inherited genetic disorders of hemoglobin.
7 Penny Stocks to Book Profits on Before 2022
Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.
IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented
Imara to Participate in Upcoming Investor Conferences
SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference
Imara to Present at Upcoming Investor Conferences
Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global...
IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host...
Source: https://incomestatements.info
Category: Stock Reports